Barton Shane 4

What Happened

• Barton Shane, BioAge Labs' Principal Accounting Officer, was granted a derivative award of 45,000 shares on Feb 17, 2026. The award was reported at a $0.00 acquisition price (no cash paid).
• This was an award/grant (SEC transaction code A), not an open-market buy or sale.

Key Details

• Transaction date: 2026-02-17; Filing date: 2026-02-19 (Form 4 appears timely).
• Price: $0.00 per share; Total reported cost: $0.
• Vesting: The award vests 1/48th monthly, with the first tranche vested on Feb 1, 2026, and monthly vesting thereafter, subject to continued service (footnote F1).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• No indication of a 10b5-1 plan, tax withholding, or immediate sale in the filing.

Context

• This is a time-based derivative award (commonly RSUs or option-style awards); vesting over 48 months means shares will be delivered (or become exercisable) gradually if the insider remains employed.
• Awards are routine compensation and do not by themselves signal intent to buy or sell shares on the open market.